دورية أكاديمية
Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines.
| العنوان: | Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines. |
|---|---|
| المؤلفون: | De la Cruz-López KG; Programa de Doctorado en Ciencias Biomédicas, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.; Laboratorio de Virus y Cáncer, Unidad de Investigación Biomédica en Cáncer. Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México & Instituto Nacional de Cancerología., Av. San Fernando No. 22 Colonia Sección XVI, Tlalpan, Mexico City, 14080, Mexico., Alvarado-Ortiz E; Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico., Valencia-González HA; Laboratorio de Células Troncales y Desarrollo Terapéutico Antineoplásico, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Secretaría de Salud, Mexico City, Mexico., Beltrán-Anaya FO; Laboratorio de Diagnóstico e Investigación en Salud, Facultad de Ciencias Químico-Biológicas, Universidad Autónoma de Guerrero, Chilpancingo de los Bravo, Gro, Mexico., Zamora-Fuentes JM; Laboratorio de Oncología Teórica, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.; Centro de Ciencias de La Complejidad, Universidad Nacional Autónoma de México, Mexico City, Mexico., Hidalgo-Miranda A; Laboratorio de Genómica de Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico., Ortiz-Sánchez E; Laboratorio de Células Troncales y Desarrollo Terapéutico Antineoplásico, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Secretaría de Salud, Mexico City, Mexico., Espinal-Enríquez J; Laboratorio de Oncología Teórica, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.; Centro de Ciencias de La Complejidad, Universidad Nacional Autónoma de México, Mexico City, Mexico., García-Carrancá A; Laboratorio de Virus y Cáncer, Unidad de Investigación Biomédica en Cáncer. Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México & Instituto Nacional de Cancerología., Av. San Fernando No. 22 Colonia Sección XVI, Tlalpan, Mexico City, 14080, Mexico. carranca@iibiomedicas.unam.mx. |
| المصدر: | BMC cancer [BMC Cancer] 2024 Jul 18; Vol. 24 (1), pp. 853. Date of Electronic Publication: 2024 Jul 18. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : BioMed Central, [2001- |
| مواضيع طبية MeSH: | Metformin*/pharmacology , Mechanistic Target of Rapamycin Complex 1*/metabolism , Mechanistic Target of Rapamycin Complex 1*/antagonists & inhibitors , Uterine Cervical Neoplasms*/drug therapy , Uterine Cervical Neoplasms*/metabolism , Uterine Cervical Neoplasms*/pathology , Uterine Cervical Neoplasms*/genetics , Xenograft Model Antitumor Assays*, Humans ; Female ; Animals ; Mice ; HeLa Cells ; Gene Expression Regulation, Neoplastic/drug effects ; Mice, SCID ; Mice, Inbred NOD ; Cell Proliferation/drug effects ; Cell Line, Tumor ; Signal Transduction/drug effects ; Sirolimus/pharmacology |
| مستخلص: | Background: Metformin, a widely prescribed antidiabetic drug, has shown several promising effects for cancer treatment. These effects have been shown to be mediated by dual modulation of the AMPK-mTORC1 axis, where AMPK acts upstream of mTORC1 to decrease its activity. Nevertheless, alternative pathways have been recently discovered suggesting that metformin can act through of different targets regulation. Methods: We performed a transcriptome screening analysis using HeLa xenograft tumors generated in NOD-SCID mice treated with or without metformin to examine genes regulated by metformin. Western Blot analysis, Immunohistochemical staining, and RT-qPCR were used to confirm alterations in gene expression. The TNMplot and GEPIA2 platform were used for in silico analysis of genes found up-regulated by metformin, in cervical cancer patients. We performed an AMPK knock-down using AMPK-targeted siRNAs and mTOR inhibition with rapamycin to investigate the molecular mechanisms underlying the effect of metformin in cervical cancer cell lines. Results: We shown that metformin decreases tumor growth and increased the expression of a group of antitumoral genes involved in DNA-binding transcription activator activity, hormonal response, and Dcp1-Dcp2 mRNA-decapping complex. We demonstrated that ZFP36 could act as a new molecular target increased by metformin. mTORC1 inhibition using rapamycin induces ZFP36 expression, which could suggest that metformin increases ZFP36 expression and requires mTORC1 inhibition for such effect. Surprisingly, in HeLa cells AMPK inhibition did not affect ZFP36 expression, suggesting that additional signal transducers related to suppressing mTORC1 activity, could be involved. Conclusions: These results highlight the importance of ZFP36 activation in response to metformin treatment involving mTORC1 inhibition. (© 2024. The Author(s).) |
| References: | Breast Cancer Res Treat. 2009 Jan;113(1):101-11. (PMID: 18256928) Nat Cell Biol. 2019 Jan;21(1):63-71. (PMID: 30602761) Am J Physiol Heart Circ Physiol. 2008 Jun;294(6):H2497-506. (PMID: 18375721) Nat Rev Mol Cell Biol. 2020 Apr;21(4):183-203. (PMID: 31937935) BMC Cancer. 2021 Jul 12;21(1):803. (PMID: 34253170) Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):507-12. (PMID: 26721670) Cancer Res. 2011 Jul 1;71(13):4366-72. (PMID: 21540236) Life Sci. 2017 Sep 15;185:53-62. (PMID: 28755883) J Mammary Gland Biol Neoplasia. 2020 Jun;25(2):163-172. (PMID: 32248342) Cell Cycle. 2010 Aug 15;9(16):3135-6. (PMID: 20865819) Methods. 2001 Dec;25(4):402-8. (PMID: 11846609) Cell. 2005 Apr 22;121(2):179-93. (PMID: 15851026) Trends Biochem Sci. 2011 Jun;36(6):320-8. (PMID: 21531565) Nat Commun. 2012 May 29;3:865. (PMID: 22643892) Nature. 2013 May 9;497(7448):217-23. (PMID: 23636326) J Clin Invest. 2010 Jul;120(7):2355-69. (PMID: 20577053) Mol Oncol. 2018 Nov;12(11):1856-1870. (PMID: 30221473) Eur J Obstet Gynecol Reprod Biol. 2019 Jun;237:33-41. (PMID: 31009857) Sci Rep. 2013;3:2070. (PMID: 23797762) Oncotarget. 2016 Sep 13;7(37):59548-59555. (PMID: 27486978) Nat Commun. 2018 Jan 31;9(1):446. (PMID: 29386513) Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102. (PMID: 28407145) Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):8977-82. (PMID: 22611195) Biochem Soc Trans. 2013 Aug;41(4):902-5. (PMID: 23863153) Nat Rev Endocrinol. 2014 Mar;10(3):143-56. (PMID: 24393785) Mol Med Rep. 2016 Mar;13(3):2590-6. (PMID: 26847819) Diabetes Care. 2011 Jun;34(6):1365-8. (PMID: 21505205) Mol Cell Biol. 2009 Aug;29(15):4308-24. (PMID: 19487463) PLoS One. 2018 May 3;13(5):e0196805. (PMID: 29723246) Aging (Albany NY). 2009 Sep 10;1(9):803-17. (PMID: 20157568) Oncogene. 2011 Mar 31;30(13):1531-41. (PMID: 21102526) Cancer Res. 1966 Aug;26(8):1787-800. (PMID: 4288553) Front Physiol. 2015 Dec 17;6:383. (PMID: 26733877) Nucleic Acids Res. 2019 Jul 2;47(W1):W191-W198. (PMID: 31066453) Life Sci. 2020 Aug 1;254:117717. (PMID: 32339541) Cell Metab. 2018 Feb 6;27(2):299-313. (PMID: 29153408) Int J Mol Sci. 2021 Mar 05;22(5):. (PMID: 33807717) Oncotarget. 2018 May 25;9(40):25808-25825. (PMID: 29899823) Genes (Basel). 2020 Aug 25;11(9):. (PMID: 32854217) FEBS J. 2018 May;285(9):1572-1588. (PMID: 29337437) Mol Biol Cell. 2019 Mar 1;30(5):542-553. (PMID: 30650008) Breast Cancer Res Treat. 2016 Feb;156(1):57-64. (PMID: 26956973) Trends Cell Biol. 2015 Sep;25(9):545-55. (PMID: 26159692) Cell. 2017 Apr 6;169(2):361-371. (PMID: 28388417) Redox Biol. 2020 Jan;28:101320. (PMID: 31526948) Cell Metab. 2020 Mar 3;31(3):472-492. (PMID: 32130880) Front Cell Dev Biol. 2020 Jul 29;8:671. (PMID: 32903688) Cell Metab. 2012 Nov 7;16(5):645-57. (PMID: 23102618) Cell Metab. 2017 Feb 7;25(2):463-471. (PMID: 28089566) Med Oncol. 2019 Nov 20;37(1):7. (PMID: 31748910) CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593) Neuroscience. 2020 Jul 15;439:275-286. (PMID: 31954828) BMC Immunol. 2019 May 2;20(1):13. (PMID: 31046669) Front Endocrinol (Lausanne). 2022 Oct 27;13:993785. (PMID: 36387876) Clin Cancer Res. 2011 Jun 15;17(12):3993-4005. (PMID: 21543517) Breast Cancer Res Treat. 2021 Jan;185(1):73-84. (PMID: 32940848) Nutrients. 2018 Jun 28;10(7):. (PMID: 29958416) |
| فهرسة مساهمة: | Keywords: AMPK-independent; Metformin; ZFP36; mTORC1 |
| المشرفين على المادة: | 9100L32L2N (Metformin) EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1) W36ZG6FT64 (Sirolimus) |
| تواريخ الأحداث: | Date Created: 20240718 Date Completed: 20240718 Latest Revision: 20240808 |
| رمز التحديث: | 20240808 |
| مُعرف محوري في PubMed: | PMC11256429 |
| DOI: | 10.1186/s12885-024-12555-5 |
| PMID: | 39026155 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1471-2407 |
|---|---|
| DOI: | 10.1186/s12885-024-12555-5 |